Drug Trial Radar · NCT07263139
Safety, Tolerability, and Exploratory Efficacy of AGP100 in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
Last checked: Nov 19, 2026Latest source record: Dec 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Jan 2, 2026
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Agiana PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Link Medical Research AB; Viedoc Technologies AB; Vitas AS
- First posted
- Dec 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted in patients with an inherited heart rhythm disorder called catecholaminergic polymorphic ventricular tachycardia (CPVT). This condition causes the heart to beat dangerously fast during situations of physical or emotional stress. CPVT is a serious condition that can limit the length and quality of patients' lives. Current treatment does not always prevent the abnormal heart rhythms that can occur as part of CPVT during strenuous exercise or stress, so new and improved medications are needed. The main questions that the trial will answer are: * How safe and tolerable is the drug AGP100; i.e, what medical problems do patients experience when taking the drug? * Does the drug help CPVT patients to maintain a normal heart rhythm while they are exercising? * How does the drug affect the levels of key heart cell signalling molecules? Patients with a diagnosis of CPVT who are aged between 18 and 75 and experience abnormal heart rhythms during exercise, despite taking a stable dose of the medication(s) prescribed by their doctor for their CPVT can take part in this trial. Participants should have normal kidney and liver function and not have high blood pressure or a diagnosis of structural heart disease. Women who are pregnant or breastfeeding cannot take part in the study. Participants who may become pregnant (and their partners) need to use highly effective methods of contraception during the study and for 90 days after the study ends. Participants will take part in the study for ten weeks. During this time, participants will be asked to take three different doses of the the drug (AGP100), as well as their normal heart medication. The drug is an oral capsule and each different dose will be taken once a day for 13 days. The study starts with participants taking a low dose for 2 weeks, then a medium dose and then a high dose. At each dose, participants will undergo a clinical examination, report any potential side effects and the treating doctor will investigate the safety, tolerability and side effects of AGP100. In total, participants will take AGP100 once a day for about six weeks. The last four weeks of the study will be a follow-up period where participants will not take AGP100. During the study, participants will need to visit the hospital six times. The visits will be three outpatient appointments and three overnight stays.
Conditions
- Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
AGP100Drug
AGP100 is a capsule for oral administration. The drug substance is formulated as an encapsulated dry powder blend composed of 5 mg or 25 mg active ingredient and inactive excipients filled into a white, opaque, size 3 hard gelatine capsule. The drug product is a white to light brown solid, with low solubility in water. During study visits, participants will take IMP under supervision of the study staff. Participants will receive with the oral dose together with water. During the rest of each treatment period, participants will self-administer the IMP. Doses should be taken with water, as needed. Participants are to continue to take the IMP once per day until they attend the study visit that starts the next treatment period/the end of study visit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events (AEs)Time frame: From Day 1 (start of treatment) through Day 68 [EoS])
- Changes in heart rate (HR)Time frame: Day 1, Day 2, Day 14, Day 15, Day 27, Day 28, Day 39 (End of Treatment), and Day 68 (EoS)
- Changes in 12-lead electrocardiogram parameters: estimated ventricular frequencyTime frame: Day 1, Day 2, Day 14, Day 15, Day 27, Day 28, Day 39 (End of Treatment), and Day 68 (EoS)
- Changes in 12-lead electrocardiogram parameters: PRTime frame: Day 1, Day 2, Day 14, Day 15, Day 27, Day 28, Day 39 (End of Treatment), and Day 68 (EoS)
- Changes in 12-lead electrocardiogram parameters: QRSTime frame: Day 1, Day 2, Day 14, Day 15, Day 27, Day 28, Day 39 (End of Treatment), and Day 68 (EoS)
- Changes in 12-lead electrocardiogram parameters: QTcTime frame: Day 1, Day 2, Day 14, Day 15, Day 27, Day 28, Day 39 (End of Treatment), and Day 68 (EoS)
- Tolerability of the IMPTime frame: From Day 1 (start of treatment) through Day 68 [EoS])
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Cardiology, Oslo University Hospital
Oslo, Norway · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.